These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
174 related articles for article (PubMed ID: 37770602)
1. Age-related results over 2 years of the multicenter Spanish study of atropine 0.01% in childhood myopia progression. Pérez-Flores I; Macías-Murelaga B; ; Barrio-Barrio J Sci Rep; 2023 Sep; 13(1):16310. PubMed ID: 37770602 [TBL] [Abstract][Full Text] [Related]
2. A multicenter Spanish study of atropine 0.01% in childhood myopia progression. Pérez-Flores I; Macías-Murelaga B; Barrio-Barrio J; Sci Rep; 2021 Nov; 11(1):21748. PubMed ID: 34741059 [TBL] [Abstract][Full Text] [Related]
3. Low-Concentration Atropine for Myopia Progression (LAMP) Study: A Randomized, Double-Blinded, Placebo-Controlled Trial of 0.05%, 0.025%, and 0.01% Atropine Eye Drops in Myopia Control. Yam JC; Jiang Y; Tang SM; Law AKP; Chan JJ; Wong E; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP Ophthalmology; 2019 Jan; 126(1):113-124. PubMed ID: 30514630 [TBL] [Abstract][Full Text] [Related]
4. Myopia Control in Caucasian Children with 0.01% Atropine Eye Drops: 1-Year Follow-Up Study. Simonaviciute D; Gelzinis A; Kapitanovaite L; Grzybowski A; Zemaitiene R Medicina (Kaunas); 2024 Jun; 60(7):. PubMed ID: 39064451 [No Abstract] [Full Text] [Related]
5. Two-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 2 Report. Yam JC; Li FF; Zhang X; Tang SM; Yip BHK; Kam KW; Ko ST; Young AL; Tham CC; Chen LJ; Pang CP Ophthalmology; 2020 Jul; 127(7):910-919. PubMed ID: 32019700 [TBL] [Abstract][Full Text] [Related]
6. Atropine for the treatment of childhood myopia: safety and efficacy of 0.5%, 0.1%, and 0.01% doses (Atropine for the Treatment of Myopia 2). Chia A; Chua WH; Cheung YB; Wong WL; Lingham A; Fong A; Tan D Ophthalmology; 2012 Feb; 119(2):347-54. PubMed ID: 21963266 [TBL] [Abstract][Full Text] [Related]
7. Differential Effects on Ocular Biometrics by 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study. Li FF; Kam KW; Zhang Y; Tang SM; Young AL; Chen LJ; Tham CC; Pang CP; Yam JC Ophthalmology; 2020 Dec; 127(12):1603-1611. PubMed ID: 32525048 [TBL] [Abstract][Full Text] [Related]
8. Topical atropine in retarding myopic progression and axial length growth in children with moderate to severe myopia: a pilot study. Fan DS; Lam DS; Chan CK; Fan AH; Cheung EY; Rao SK Jpn J Ophthalmol; 2007; 51(1):27-33. PubMed ID: 17295137 [TBL] [Abstract][Full Text] [Related]
9. Effect of Low-Concentration Atropine Eye Drops in Controlling the Progression of Myopia in Children: A One- and Two-Year Follow-Up Study. Zhang H; Yang P; Li Y; Zhang W; Li S Ophthalmic Epidemiol; 2024 Jun; 31(3):240-248. PubMed ID: 37528608 [TBL] [Abstract][Full Text] [Related]
10. Effect of low-dose atropine on myopia progression, pupil diameter and accommodative amplitude: low-dose atropine and myopia progression. Fu A; Stapleton F; Wei L; Wang W; Zhao B; Watt K; Ji N; Lyu Y Br J Ophthalmol; 2020 Nov; 104(11):1535-1541. PubMed ID: 32086237 [TBL] [Abstract][Full Text] [Related]
11. Analysis of treatment response about low-dose (0.01%) atropine eye-drops in myopic children. Jeon GS; Hong IH; Lee JH; Song TG; Lee TY; Han JR Eur J Ophthalmol; 2022 Jul; 32(4):2011-2017. PubMed ID: 34399596 [TBL] [Abstract][Full Text] [Related]
12. Myopia progression and axial elongation in Spanish children: Efficacy of atropine 0.01% eye-drops. Moriche-Carretero M; Revilla-Amores R; Diaz-Valle D; Morales-Fernández L; Gomez-de-Liaño R J Fr Ophtalmol; 2021 Dec; 44(10):1499-1504. PubMed ID: 34774348 [TBL] [Abstract][Full Text] [Related]
13. Atropine for the treatment of childhood myopia: effect on myopia progression after cessation of atropine. Tong L; Huang XL; Koh AL; Zhang X; Tan DT; Chua WH Ophthalmology; 2009 Mar; 116(3):572-9. PubMed ID: 19167081 [TBL] [Abstract][Full Text] [Related]
14. Effect of Atropine 0.01% Eye Drops on the Difference in Refraction and Axial Length between Right and Left Eyes. Liang X; Wei S; Li SM; An W; Du J; Sun Y; Gan J; Bai W; Cai Z; Song Q; Yin L; Wang N Ophthalmic Res; 2023; 66(1):496-505. PubMed ID: 36603556 [TBL] [Abstract][Full Text] [Related]
15. Five-Year Clinical Trial of the Low-Concentration Atropine for Myopia Progression (LAMP) Study: Phase 4 Report. Zhang XJ; Zhang Y; Yip BHK; Kam KW; Tang F; Ling X; Ng MPH; Young AL; Wu PC; Tham CC; Chen LJ; Pang CP; Yam JC Ophthalmology; 2024 Sep; 131(9):1011-1020. PubMed ID: 38494130 [TBL] [Abstract][Full Text] [Related]
16. Effect of Low-Concentration Atropine Eyedrops vs Placebo on Myopia Incidence in Children: The LAMP2 Randomized Clinical Trial. Yam JC; Zhang XJ; Zhang Y; Yip BHK; Tang F; Wong ES; Bui CHT; Kam KW; Ng MPH; Ko ST; Yip WWK; Young AL; Tham CC; Chen LJ; Pang CP JAMA; 2023 Feb; 329(6):472-481. PubMed ID: 36786791 [TBL] [Abstract][Full Text] [Related]
17. Atropine for the treatment of childhood myopia. Chua WH; Balakrishnan V; Chan YH; Tong L; Ling Y; Quah BL; Tan D Ophthalmology; 2006 Dec; 113(12):2285-91. PubMed ID: 16996612 [TBL] [Abstract][Full Text] [Related]
18. Risk factors for progressive myopia in the atropine therapy for myopia study. Loh KL; Lu Q; Tan D; Chia A Am J Ophthalmol; 2015 May; 159(5):945-9. PubMed ID: 25640408 [TBL] [Abstract][Full Text] [Related]
19. Myopia outcome study of atropine in children: Two-year result of daily 0.01% atropine in a European population. Loughman J; Kobia-Acquah E; Lingham G; Butler J; Loskutova E; Mackey DA; Lee SSY; Flitcroft DI Acta Ophthalmol; 2024 May; 102(3):e245-e256. PubMed ID: 37694816 [TBL] [Abstract][Full Text] [Related]
20. Age Effect on Treatment Responses to 0.05%, 0.025%, and 0.01% Atropine: Low-Concentration Atropine for Myopia Progression Study. Li FF; Zhang Y; Zhang X; Yip BHK; Tang SM; Kam KW; Young AL; Chen LJ; Tham CC; Pang CP; Yam JC Ophthalmology; 2021 Aug; 128(8):1180-1187. PubMed ID: 33422558 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]